Protocol 603 is enrolling subjects with moderate-to-severe Crohn's disease who are intolerant to, or have previously failed therapy with, at least one steroid and at least one immunosuppressant and a biologic monoclonal anti-body to tumor necrosis factor alpha. The protocol investigates the safety and efficacy of using PROCHYMAL® adult human stem cells to induce remission. PROCHYMAL is delivered through a vein in the arm four times over two weeks, for approximately an hour each time.
A Phase III, Multicenter, Placebo-controlled, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of PROCHYMAL® (ex Vivo Cultured Adult Human Mesenchymal Stem Cells) Intravenous Infusion for the Induction of Remission in Subjects Experiencing Treatment-refractory Moderate-to-severe Crohn's Disease
A significant number of individuals with Crohn's disease do not find relief with existing steroidal, immunosuppressive, or biologic therapies, and are forced to seek surgery or other drastic measures for treatment.
PROCHYMAL® adult human stem cells are manufactured from healthy, volunteer donors, extensively tested, and are stored to be available as needed. Human and animal studies have shown that the cells do not require any donor-recipient matching. The cells may have both immunosuppressive and healing benefits in Crohn's disease. The cells naturally migrate specifically to sites of inflammation, so their effects are believed to be local and self-limiting rather than systemic.
Protocol 603 is enrolling subjects to evaluate the ability of PROCHYMAL to induce remission in subjects with moderate-to-severe disease (Crohn's disease activity index -- CDAI -- of between 250 and 450, inclusive) who have failed or been intolerant of at least one drug in each of the steroid, immunosuppressant, and biologic classes.
Crohn's Diseaseadult stem cell therapy
You can join if…
Open to people ages 18–70
failed (within last 2 yr) or intolerant of at least one steroid AND at least one immunosuppressant AND at EXACTLY one biologic
CDAI between 250 and 450, inclusive
endoscopically or radiographically confirmed Crohn's disease of ileus or colon or both
CRP of at least 5 mg/l (0.5 mg/dl)OR CDAI of at least 300
weight between 40 and 150 kg, inclusive
adequate renal function
negative PPD test (or evaluated low risk of TB activation)
You CAN'T join if...
HIV or hepatitis infection active
allergy to CT contrast agents, or to bovine or porcine products
symptomatic fibrostenotic Crohn's disease
biologic therapy within past 90 d
prednisone greater than 20 mg/d within past month
total parenteral nutrition
abnormal liver function
malignancy active within past 5 years (except completely resected basal or squamous cell carcinoma of skin)
enteric pathogens, including C. difficile
history of colonic mucosal dysplasia
current or prior evidence of TB (unless risk of activation or re-activation deemed low)
University of California, San Francisco San Francisco, California, 94115, United States
University of Southern California University Hospital Los Angeles, California, 90033, United States